/L and his granulocytes had reduced expression of CD11b, CD11a and CD18 supporting a diagnosis of LAD-1. His childhood was remarkable for over 100 hospitalizations for recurrent severe skin and soft tissue infections requiring i.v. antibiotics and occasionally minor surgeries for drainage of abscesses. At age 13, he was diagnosed with Crohn's disease, which was confirmed by histology. His requirement for immunosuppressive medications and need for central venous catheters gave rise to further complications including lifethreatening bacteremia, mediastinitis and recurrent ulcerative esophageal candidiasis. He also developed two episodes of upper limb venous thrombosis secondary to central venous catheters. He required two ileal resections for stricture formation and bowel obstruction. For the past four years, his LAD-1 has been managed with daily s.c. granulocyte colony stimulating factor injections, resulting in an improvement in the number of severe infections requiring hospitalization and i.v. antibiotics to about 4-5 times a year.
Prior therapy for Crohn's disease included steroids, 5-ASA derivatives, 6 mercaptopurine, adalimumab and infliximab. Adalimumab was discontinued due to side effects of respiratory distress and arthralgia, although it achieved some degree of disease control. Infliximab therapy was complicated by recurrent severe candida esophagitis. He did not have any other medical problems and had an ECOG performance status of 1.
The CBT took place in July 2009. The patient's only sibling had ulcerative colitis, so was not a candidate for a matched sibling donor. Instead, two umbilical cord blood units were utilized to complete the CBT. The transplant protocol was approved by the IRB at Northwestern University, Chicago, IL, USA. The conditioning regimen consisted of fludarabine 120 mg/m 2 , i.v. and CY 200 mg/ kg i.v. given over 4 days from day À 5 to À 2. GVHD prophylaxis was alemtuzumab 30 mg i.v. on days À 3 and À 2, CYA 200 mg twice a day starting on day À 3 and tapered to achieve trough levels between 150-200 u/L and continued for 180 days and mycophenolate 1000 mg twice a day from day À 1 and continued for 6 months. The transplanted cell dose was 0.34 million/kg CD34 þ unselected cells from cord blood units. Both units of cord blood were 6/6 HLA matched.
Neutrophil engraftment occurred on day þ 14 post transplant (ANC4500). The post-transplant period was complicated by maxillary sinusitis and fungal esophagitis which required a second hospitalization. Chimerism studies after the transplant did not detect donor cells from one of the cord blood unit; however, there was successful chimerism with the second donor unit (Table 1) . Mycophenolate and CYA were discontinued 2 months after the transplant as there was no GVHD, and the patient had been hospitalized for esophageal candidiasis.
Clinically, the patient has had fewer infections and hospitalizations after the HSCT. For the first two years post transplant, he has had four hospitalizations; all four hospitalizations were within the first year of follow up. His Crohn's disease went into remission which was confirmed by repeat endoscopy and biopsies. In addition, he remains off all immunosuppressive medications for Crohn's disease without any nausea, diarrhea or abdominal pain. His weight has been stable and he does not have any fistulas. He continue to be on low dose granulocyte colony stimulating factor injections at 100 mcg s.c. daily.
Allogeneic HSCT for LAD-1 has been reported in children (Table 2 ). Most cases have reported myeloablative regimens for conditioning. Recently, HSCT for LAD-1 using non myeloablative regimens have been reported which achieved mixed chimerism. 10 Out of 10 only one patient was transplanted using cord blood who did not engraft and died4 months after transplant.
Complications after HSCT include treatment related mortality and GVHD, both of which are a function of conditioning regimens and GVHD prophylaxis. We used a non-myeloablative conditioning regimen to reduce treatment related morbidity. We saw durable engraftment with low level mixed chimerism which was sufficient for correction of the underlying immune defect. There is a reported decreased incidence of acute GVHD in CBT compared with matched unrelated donor HSCT. However, there are reports of increased chronic GVHD in CBT as compared with matched unrelated donor HSCT. We used alemtuzumab in the conditioning regimen, along with CYA and mycophenolate prophylaxis. We did not observe GVHD in our patient and were able to stop prophylaxis after 2 months.
This report shows that CBT can be successful using a nonmyeloabalative regimen for LAD-1 patients. Low level mixed chimerism attained by reduced intensity conditioning was sufficient to ameliorate the immune defect. Umbilical cord blood is less restricted with respect to HLA matching and is more readily available. It could be a feasible alternative source of stem cells for LAD-1 patients who do not have a matched sibling donor.
The patient had a CR of Crohn's disease following CBT. The cause of remission of Crohn's disease is not clear. The immunosuppression delivered by the conditioning regimen or mixed chimerism with donor cells could be responsible for this effect. Autologous HSCT has been reported to induce remission in severe Crohn's disease in patients refractory to tumor necrosis factor inhibitors. [12] [13] [14] [15] However, there was a significant relapse rate. Although there are ongoing studies of allogeneic HSCT in severe Crohn's disease (ClinicalTrials.gov Identifier: NCT01288053), there are no reports of use of CBT for Crohn's disease. 
